Neutralising antibody responses to two doses of measles vaccine at 5 and 13 months of age in the United Kingdom.
Fifty-three children born in the United Kingdom between April 1993 and July 1994 were given two doses of measles vaccine, at 5 and 13 months of age, and their neutralising antibody reports were studied to assess the feasibility of protecting infants (aged 1 to 11 months) in the event of an outbreak or who were due to travel abroad. Sixteen infants responded at 5 months, an additional 35 responded at 13 months and two did not respond. The responses were inversely related to the levels of maternal antibodies (p < 0.0001). Infants who responded at 5 months also produced higher responses at 13 months than those who did not respond initially (p = 0.0001). No serious side effects were encountered. These data suggest that measles vaccine protects 30% of infants at 5 months and that a second dose at 13 months results in almost universal seroconversion.